Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vebicorvir - Assembly Biosciences

Drug Profile

Vebicorvir - Assembly Biosciences

Alternative Names: ABI-H0731; VBR

Latest Information Update: 08 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Indiana University
  • Developer Antios Therapeutics; Assembly Biosciences
  • Class Amides; Antivirals; Small molecules; Thiazepines; Thiazoles
  • Mechanism of Action Viral core protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 31 Dec 2023 BeiGene receives a termination notice from Assembly Biosciences for License and Collaboration Agreement in China for development and commercialisation of ABI H0731, ABI H2158, and ABI H3733
  • 10 Nov 2023 Efficacy and adverse events data from phase-IIa trial in Hepatitis-B presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
  • 06 Oct 2023 Assembly Biosciences terminates a phase-II clinical trial in Hepatitis B (Combination therapy) in China (PO) by the study Sponsor for strategic reasons to prioritize research and development efforts on finite and curative HBV therapies (NCT04781647)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top